September is Pulmonary Fibrosis Awareness Month, and organizations around the world are gearing up to educate others and bring…
Articles by Marisa Wexler, MS
Treatment with GRI Bio‘s investigational oral therapy GRI-0621 appears to reduce markers of fibrosis, or scarring, in people with…
An experimental oral therapy for idiopathic pulmonary fibrosis (IPF) has been tolerated well in an ongoing Phase 2 clinical…
Starting this week and over the coming months, the Pulmonary Fibrosis Foundation (PFF) will be hosting the PFF Walk…
Basal stem cells taken from the upper part of a patient’s respiratory tract can be expanded in the lab and…
Enrollment is now complete in a Phase 2b clinical trial, dubbed CORAL, that’s testing nalbuphine extended-release (ER) tablets — planned…
A protein called Runx2 contributes to the abnormal activity of lung cells that drive pulmonary fibrosis, a new study…
Nerandomilast, an oral treatment being developed by Boehringer Ingelheim, bested a placebo at preserving lung function in adults with…
Mediar Therapeutics is planning to launch a Phase 2 clinical trial to test its experimental therapy MTX-463 in people…
CAL101, an investigational therapy with the potential to treat pulmonary fibrosis, showed a favorable safety and pharmacological profile in…